Skip to main content

Table 1 Clinical characteristics of study population at baseline

From: Borderline pulmonary hypertension is associated with exercise intolerance and increased risk for acute exacerbation in patients with interstitial lung disease

Variables

Total

No-PH

Bo-PH

PH

p-value*

  

mPAP ≤20

20 < mPAP < 25

mPAP ≥25

 

Subjects, N (%)

80

56

18

6

Mean age (years)

71.2 ± 10.3

70.7 ± 11.0

76.7 ± 6.46

73.4 ± 5.32

0.916

BMI (kg/m2)

22.5 ± 3.99

21.9 ± 3.38

21.4 ± 2.99

22.7 ± 4.11

0.182

Smoking status, current/former/never

6/40/34

5/25/26

1/10/7

0/5/1

0.352

Underlying disease

 IPF, N (%)

23 (28.8)

17 (30.3)

2 (11.1)

4 (66.7)

0.030

 CPFE, N (%)

8 (10.0)

5 (8.9)

2(11.1)

1 (16.7)

0.822

 CTD-ILD, N (%)

15 (18.8)

11 (19.6)

4 (22.2)

0 (0)

0.459

 Other ILD, N (%)

34 (42.5)

23 (41.1)

10 (55.6)

1 (16.7)

0.230

KL-6 (U/ml)

1030(628, 1569)

968 (660, 1448)

965 (420, 1575)

1280(909, 1526)

0.521

PaO2(mmHg)

75.4 ± 9.2

76.7 ± 9.3

73.0 ± 9.0

73.1 ± 9.9

0.117

VC, % predicted (%)

74.6 ± 22.9

72.7 ± 22.5

67.9 ± 23.8

79.3 ± 19.0

0.436

FEV1, % predicted (%)

90.3 ± 25.3

87.8 ± 26.1

84.5 ± 18.1

93.5 ± 24.5

0.637

TLC, % predicted (%)

76.9 ± 17.7

76.0 ± 16.2

74.3 ± 21.2

78.6 ± 14.4

0.966

DLco, % predicted (%)

50.5 ± 22.6

52.5 ± 24.2

48.2 ± 24.3

41.3 ± 22.6

0.530

6MWD (m)

342.0 ± 130.1

383.8 ± 101.6

235.2 ± 95.3

169.2 ± 140.0

< 0.0001

ΔSpO2(%)

7.60 ± 4.06

7.31 ± 4.00

10.0 ± 4.14

9.80 ± 2.28

0.024

RVSP (mmHg)

30 (24, 35)

28 (22.5, 33)

33 (30, 38)

48.5 (38.8, 52.3)

< 0.0001

mPAP(mmHg)

16.5 (14, 21)

15 (13, 17)

21 (21, 22)

27.5 (25.5, 28.8)

< 0.0001

PVR (dynes・sec・cm−5)

195 (152, 287)

180 (145, 210)

281 (211, 317)

378 (320, 494)

< 0.0001

Cardiac index(l/min/m2)

2.54 (2.27, 2.76)

2.51 (2.21, 2.71)

2.71 (2.54, 3.01)

2.64 (2.17, 2.74)

0.035

PAWP (mmHg)

6.23 ± 2.68

5.93 ± 2.62

7.46 ± 2.96

4.60 ± 1.82

0.056

  1. Data are presented as mean ± standard deviation or median (interquartile range). *p-value is comparison among the three groups (No-PH, Bo-PH, and PH groups). Definition of abbreviations: PH, pulmonary hypertension; BMI, body mass index; IPF, idiopathic pulmonary fibrosis; CPFE, combined pulmonary fibrosis and emphysema; ILD, interstitial lung disease; CTD-ILD, connective tissue disease associated with ILD; KL-6, krebsvon den lungen-6; PaO2, partial pressure of oxygen; VC, vital capacity; FEV1, forced expiratory volume in 1 s;TLC, total lung capacity; DLco, diffusing capacity for carbon monoxide; 6MWD, 6-min walk distance; SpO2, oxygen saturation as measured by pulse oximeter;ΔSpO2, initial SpO2–lowest SpO2on 6-min walk test; RVSP, right ventricular systolic pressure; mPAP, mean pulmonary artery pressure; PVR, pulmonary vascular resistance; PAWP, pulmonary arterial wedge pressure